arrow
B

Bing-Zong Li

Department of Hematology
H指数:31
被引数:3,756

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG)

体质量指数与淋巴瘤相关性噬血细胞性淋巴组织细胞增生症结局的关系:一项江苏省淋巴瘤协作组(JCLG)的多中心回顾性队列研究

2026-02-270
PRE
Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)

泽布替尼、来那度胺和利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松作为非生发中心B细胞弥漫大B细胞淋巴瘤的初始治疗方案:一项由江苏省淋巴瘤协作组(JCLG)开展的多中心II期研究

2025-10-260
OAAI
Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma Group

内皮激活和应激指数作为淋巴瘤相关性噬血细胞性淋巴组织细胞增多症的生存预测因子:一项江苏省淋巴瘤协作组的多中心回顾性队列研究

2025-09-080
PRE
An anti-CD19-exosome delivery system navigates the blood-brain barrier for targeting of central nervous system lymphoma

一种抗CD19外泌体递送系统能够穿越血脑屏障,以靶向中枢神经系统淋巴瘤

2025-03-052
OA
Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

维奈克拉联合HAG方案在新诊断ETP-ALL中的应用:一项前瞻性、多中心、II期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Artificial intelligence for diagnosis and prognosis prediction of natural killer/T cell lymphoma using magnetic resonance imaging
2024-05-012
OAAI
Multi-center study of COVID-19 infection in elderly patients with lymphoma: on behalf of Jiangsu Cooperative Lymphoma Group (JCLG)
2024-04-220
PRE